Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. demonstrated a positive trajectory in test volume, with EsoGuard tests increasing by 2% year-over-year to 2,841 in 3Q25, reflecting consistent growth despite fluctuations in prior quarters. The company's ongoing efforts to expand insurance coverage, particularly with Medicare, are poised to accelerate revenue growth, narrowing the gap between revenue and test volume increases. Furthermore, a favorable outcome from the MolDX CAC meeting indicates promising potential for enhanced coverage and engagement, suggesting significant upside potential for Lucid Diagnostics amid its commercialization efforts.

Bears say

Lucid Diagnostics experienced a disappointing performance in 3Q25, with revenue falling below consensus expectations while the company reported a stable cash burn and a pro forma net loss of $10.3 million, which was greater than its previous projections. The decline in EsoGuard test processing, evidenced by a drop from 3,034 tests in Q1 to 2,756 tests in Q2, raises concerns about market adoption and demand for their primary product. Additionally, multiple risks, such as potential insurance coverage challenges, ineffective marketing strategies, and increasing competition, could further hinder the company’s financial stability and growth prospects.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Jan 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.